@cancercolab

cancercolab has been a member of Linktree for 7 years and joined in February 2019. The social media accounts linked to from cancercolab are: Instagram, YouTube, LinkedIn, Bluesky. Besides social media accounts, cancercolab has populated their site with rethinking value in HTA, the case for a national precision oncology strategy | knowyourgenome.co, what you can do - POAM25, HOME | knowyourgenome.co, partner activation kit #KNOWvember #POAM25, rethinking how we define value in HTA (Chinese (simplified), Portuguese, Polish, Japanese, Korean, Spanish (Mexico), Swedish, Spanish), rethinking how we define value in HTA (English, French (France and Canada), Catalan, Dutch, German, Greek, Italian, Portuguese (Brazil)), patient engagement in HTA. report & recommendations, patient engagement in HTA. executive summary, S3E4 side effects may include..., S3.E3 fact vs feed. the health misinformation and disinformation problem, going viral. understanding viral vectors in cancer care, It'S #KNOWvember - this November know your genome!, behind the mciroscope. a conversation with pathologist Dr Carol Cheung, CBQA webinar precision diagnostics in oncology -who pays?, DISRUPT | The Patient Centricity Project, shaping tomorrow. the role of CAR-T in myeloma, COLAB.CONVERSATIONS S2E7. patient centricity. are we there yet?, A Letter To the Decision Makers Whose Decisions Can Impact The Lives Of Canadians Living with Cancer, To Those With The Power to Reshape The Landscape of Cancer Care in Canada, S2E4. shifting the conversation from cost to value, WEBINAR. IMPACT DRIVING PATIENT ADVOCACY SUSTAINABILITY, S2E3 creating space for women's health in healthcare, HERhealth. sarah's story experience of women with cancer, HERhealth. alvina's story. experience of women with cancer., HERhealth. michelle's story. experience of women with cancer, the cancer collaborative: we're going to have to work together for a better cancer system in canada, why gender disparities in health matter, COLAB.CONVERSATIONS | colabcolab.conversations now available everywhere you like to watch/listen, colab.conversations now available on Spotify!, Opinion: COVID-19 is a blueprint for healthcare transformation, S1E4. a prescription for change. patient centered clinical trials and its impact for patients, S1.E3 unmute. amplifying the patient voice, CRISIS TO CATALYST. USING LESSONS LEARNED FROM COVID19 TO PRIORITIZE CANCER CARE IN CANADA. READ THE FULL PAPER, CRISIS TO CATALYST. HOW COVID19 TAUGHT US WE NEED TO DO BETTER FOR CANADIANS LIVING WITH CANCER. press release, PODCAST. COLAB.CONVERSATIONS, Opinion: CAR T-cell therapy delays jeopardize lives of Canadians with blood cancer, WATCH. looking back to move forward. learning from the implementation of CART in Canada, REGISTER. looking back to move forward. learnings from the implementation of CAR-T across Canada, WATCH. Evolution of CAR T cell therapies and future directions, REGISTER. evolution of CAR T-CELL therapies and future directions, #ASCO23, FLIPPING THE SCRIPT. PUTTING THE U IN VALUE FRAMEWORKS, Project Orbis. Accelerating time to patient access? | colab, when to talk to your healthcare team about biomarker testing, why precision medicine matters, colorectal cancer canada survey results on molecular profiling in canada, the importance of biomarker testing, let’s talk about biomarkers - BRCA, tumour agnostic therapies are redefining cancer care, current biomarkers in cancer, understanding targeted therapies, understanding biomarkers, understanding precision medicine, precision medicine awareness month 2021, what are biomarkers, what is precision medicine awareness month, colab.notebook ASCO20 EDITION, COVID 19 resources for the cancer community, colab statement on COVID 19, data collection in the age of RWE. HTA engagement. a colab series, biosimilars can significantly reshape our healthcare systems, #Cracking the Cancer Code, if not now, when?, car-t. one year later, IEEPO recap- further thoughts on the promise of personalised medicines, it's that time of year. ASCO 2019, the promise of personalized medicine, car-t. hype or hope, approval ≠ funding, the car-t revolution. shifting conversations., new technology. old framework?, biosimilars. the european experience, being a change catalyst, managing innovation in oncology [mio], about a community that created change, challenges & potential barriers to access.